Evidence map›Paper›PMID 40836376›Full record

Observational studyInternational journal of dermatology2026

Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective Study.

Luca Potestio, Cataldo Patruno, Marika Del Gaudio, Michela Ortoncelli, Simone Ribero, Francesca Barei, Silvia Mariel Ferrucci, Laura Bonzano, Ilaria Trave, Mario Bruno Guanti and 41 more

Abstract readObservational StudyMulticenter StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in International journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

51 authors.

Luca PotestioSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.ORCID https://orcid.org/0000-0001-5940-0592
Cataldo PatrunoDepartment of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, Campobasso, Italy.ORCID https://orcid.org/0000-0001-8661-2822
Marika Del GaudioSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Michela OrtoncelliDepartment of Medical Sciences, Dermatology Clinic, University of Turin, Turin, Italy.
Simone RiberoDepartment of Medical Sciences, Dermatology Clinic, University of Turin, Turin, Italy.ORCID https://orcid.org/0000-0002-0098-1406
Francesca BareiDermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.ORCID https://orcid.org/0000-0002-7188-7310
Silvia Mariel FerrucciDermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Laura BonzanoDermatology Unit, Arcispedale Santa Maria Nuova, Azienda USL-IRCCS Reggio Emilia, Reggio Emilia, Italy.ORCID https://orcid.org/0000-0002-8933-4626
Ilaria TraveSection of Dermatology, Department of Health Sciences (DISSAL), University of Genoa, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.ORCID https://orcid.org/0000-0002-5469-4517
Mario Bruno GuantiDepartment of Dermatology, University of Modena and Reggio Emilia, Modena, Italy.
Carlotta GurioliDermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Bianca Maria PiracciniDermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.ORCID https://orcid.org/0000-0001-6537-9689
Niccolò GoriDermatology, University Department of Translational Medicine and Surgery, Sacred Heart Catholic University, Rome, Italy.ORCID https://orcid.org/0000-0003-1987-0623
Elena IppolitiDermatology, University Department of Translational Medicine and Surgery, Sacred Heart Catholic University, Rome, Italy.
Ketty PerisDermatology, University Department of Translational Medicine and Surgery, Sacred Heart Catholic University, Rome, Italy.ORCID https://orcid.org/0000-0003-1957-6600
Laura GrigolatoDermatology Unit, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy.
Mariateresa RossiDermatology Unit, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy.ORCID https://orcid.org/0000-0002-5101-159X
Caterina FotiSection of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", Bari, Italy.ORCID https://orcid.org/0000-0001-6196-9788
Paolo RomitaSection of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", Bari, Italy.
Benedetta TironeSection of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", Bari, Italy.ORCID https://orcid.org/0009-0009-1162-1121
Eustachio NettisRegional Reference Center for Allergic and Immunological Diseases, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", Bari, Italy.
Maria EspositoDepartment of Biotechnological and Applied Clinical Sciences, University of L' Aquila, L' Aquila, Italy.ORCID https://orcid.org/0000-0002-4773-6993
Maria Concetta FargnoliDepartment of Biotechnological and Applied Clinical Sciences, University of L' Aquila, L' Aquila, Italy.ORCID https://orcid.org/0000-0002-7249-2556
Lina Maria MagnanimiDepartment of Biotechnological and Applied Clinical Sciences, University of L' Aquila, L' Aquila, Italy.
Elena PezzoloDepartment of Dermatology, San Bortolo Hospital, Vicenza, Italy.
Katharina HanselDermatology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Luca StingeniDermatology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.ORCID https://orcid.org/0000-0001-7919-8141
Rosanna SattaDepartment of Medical, Surgical, and Experimental Sciences, University of Sassari, Sassari, Italy.
Maria MarianoClinical Dermatology, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.
Flavia PigliacelliClinical Dermatology, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.
Flavia Manzo MargiottaDepartment of Dermatology, University of Pisa, Pisa, Italy.ORCID https://orcid.org/0000-0002-9593-9357
Marco RomanelliDepartment of Dermatology, University of Pisa, Pisa, Italy.
Ruggero Cascio IngurgioDermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.ORCID https://orcid.org/0009-0000-1438-9553
Antonio CostanzoDermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
Alessandra NarcisiDermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
Monica CorazzaSection of Dermatology, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Emiliano AntigaSection Dermatology, Department of Health Sciences, University of Florence, Florence, Italy.ORCID https://orcid.org/0000-0001-7787-4433
Pietro MorroneDermatology, Azienda Provinciale di Cosenza, Cosenza, Italy.
Pietro RubegniDermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.
Laura CalabreseDermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.
Laura LazzeriDermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.
Giovanni RubegniOphthalmology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
Fabrizio GuarneriDepartment of Clinical & Experimental Medicine, Section of Dermatology, University of Messina, Messina, Italy.
Nicola ZerbinatiDepartment of Medicine and Innovation Technology (DiMIT), University of Insubria, Varese, Italy.
Andrea CarugnoDepartment of Medicine and Surgery, University of Insubria, Varese, Italy.
Rosa Valentina PucaDepartment of Dermatology and Dermosurgery, AOSG San Giuseppe Moscati, Avellino, Italy.
Oriele SarnoDepartment of Dermatology and Dermosurgery, AOSG San Giuseppe Moscati, Avellino, Italy.
Claudio MarascaDermatology Unit, Medical Department, National Hospital "A. Cardarelli" of Naples, Naples, Italy.ORCID https://orcid.org/0000-0002-8401-5730
Emanuela MartinaDermatology Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.ORCID https://orcid.org/0000-0003-0815-172X
Francesca di VicoSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Maddalena NapolitanoSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.ORCID https://orcid.org/0000-0003-3309-8190

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundConjunctivitis is among the most frequent adverse events (AEs) emerged in clinical trials for all biologic drugs approved for atopic dermatitis (AD). However, real-world comparative data on the incidence, risk factors, and management of conjunctivitis remain limited.

objectiveWe aimed to compare the incidence, clinical features, and management of conjunctivitis in patients with moderate-to-severe AD treated with dupilumab or tralokinumab in a real-life setting. PATIENTS AND

methodsA multicenter, retrospective, observational study including adult patients with moderate-to-severe AD treated with dupilumab or tralokinumab for at least 16 weeks was carried out. Demographic, clinical, and therapeutic data were collected from 35 dermatological referral centers across Italy. Conjunctivitis incidence, severity, time to onset, and ophthalmologic management were analyzed and compared between treatment groups.

resultsA total of 6668 patients were included (5899 on dupilumab and 769 on tralokinumab). Conjunctivitis occurred in 10.76% of dupilumab-treated and 12.61% of tralokinumab-treated patients, with no statistically significant difference in overall incidence. However, time to onset was significantly shorter with tralokinumab than with dupilumab (15.3 ± 14.5 weeks vs. 35.5 ± 45.2 weeks, respectively; p < 0.0001). Ophthalmologic management strategies were similar between groups, mainly involving lubricants and corticosteroid-based eye drops. Dupilumab-treated patients more frequently discontinued or switched treatment due to conjunctivitis than tralokinumab patients (25.4% vs. 14.4%, respectively; p < 0.05).

conclusionsConjunctivitis represents a relatively frequent AE in patients with AD receiving dupilumab or tralokinumab. However, earlier onset of conjunctivitis with tralokinumab and higher discontinuation rates with dupilumab suggest differing tolerability profiles. Early recognition of ocular symptoms is essential, and dermatologists should promptly initiate supportive eye care and refer to ophthalmologists when appropriate to avoid unnecessary treatment interruptions.

Indexed as

Antibodies, Monoclonal, HumanizedConjunctivitisDermatitis, AtopicAdultAntibodies, MonoclonalFemaleHumansIncidenceItalyMaleMiddle AgedRetrospective StudiesRisk FactorsSeverity of Illness IndexYoung AdultAntibodies, MonoclonalAntibodies, Monoclonal, Humanizeddupilumabtralokinumab

Identifiers

PMID40836376
PMCPMC12783438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.